Stock News

Emergent Biosolutions (EBS) Gets Argus Research Civerage with $62.0000 Target; Steven Madden, Ltd. (SHOO) Had 11 Bullish Analysts

Steven Madden, Ltd. (NASDAQ:SHOO) Logo

Argus Research shared with investors and clients in a recent note that it has begun coverage on Emergent Biosolutions (NYSE:EBS) stock, with a “Buy” rating and a $62.0000 price target.

Among 16 analysts covering Steven Madden (NASDAQ:SHOO), 11 have Buy rating, 0 Sell and 5 Hold. Therefore 69% are positive. Steven Madden had 58 analyst reports since August 12, 2015 according to SRatingsIntel. Jefferies maintained the shares of SHOO in report on Tuesday, October 31 with “Hold” rating. The stock has “Hold” rating by KeyBanc Capital Markets on Wednesday, October 18. The company was maintained on Wednesday, August 2 by Buckingham Research. The firm earned “Buy” rating on Tuesday, February 13 by Canaccord Genuity. Buckingham Research downgraded Steven Madden, Ltd. (NASDAQ:SHOO) on Monday, July 18 to “Neutral” rating. The stock of Steven Madden, Ltd. (NASDAQ:SHOO) earned “Buy” rating by Susquehanna on Tuesday, January 9. The firm has “Outperform” rating given on Thursday, February 25 by Telsey Advisory Group. As per Monday, June 5, the company rating was maintained by Canaccord Genuity. Jefferies maintained Steven Madden, Ltd. (NASDAQ:SHOO) on Wednesday, June 14 with “Hold” rating. On Tuesday, January 2 the stock rating was maintained by Jefferies with “Hold”. See Steven Madden, Ltd. (NASDAQ:SHOO) latest ratings:

07/06/2018 Broker: Canaccord Genuity Rating: Buy New Target: $59.0000 Maintain
04/06/2018 Broker: Loop Capital Markets Rating: Hold New Target: $49.0000 Initiate
23/04/2018 Broker: FBR Capital Rating: Buy New Target: $55.0000 Maintain
23/04/2018 Broker: Canaccord Genuity Rating: Buy New Target: $54.0000 Maintain
18/04/2018 Broker: Citigroup Rating: Buy New Target: $56.0000 Reinitiate
18/04/2018 Broker: Buckingham Research Old Rating: Buy New Rating: Buy New Target: $53 Reinitiate
16/04/2018 Broker: Canaccord Genuity Rating: Buy New Target: $52.0000 Maintain
28/02/2018 Broker: FBR Capital Rating: Buy Maintain
28/02/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $50 New Target: $52 Maintain
13/02/2018 Broker: Canaccord Genuity Rating: Buy Maintain

Emergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. The company has market cap of $2.61 billion. The Company’s products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. It has a 30.75 P/E ratio. The companyÂ’s marketed products include BioThrax, an anthrax vaccine; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT for the treatment of botulinum disease; vaccinia immune globulin intravenous that addresses adverse events from smallpox vaccination; reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride.

Since January 2, 2018, it had 0 insider buys, and 11 selling transactions for $4.28 million activity. Zoon Kathryn C sold $19,857 worth of stock or 376 shares. Another trade for 15,785 shares valued at $822,615 was sold by Abdun-Nabi Daniel. $434,115 worth of Emergent BioSolutions Inc. (NYSE:EBS) was sold by Richard Ronald on Tuesday, April 17. 1,898 shares valued at $93,951 were sold by Havey Adam on Tuesday, February 27. Shares for $436,876 were sold by Hauer Jerome M on Tuesday, June 5. JOULWAN GEORGE A had sold 5,000 shares worth $264,448 on Monday, June 11.

The stock decreased 5.72% or $3.18 during the last trading session, reaching $52.46. About 627,748 shares traded or 96.94% up from the average. Emergent BioSolutions Inc. (NYSE:EBS) has risen 65.53% since June 16, 2017 and is uptrending. It has outperformed by 52.96% the S&P500. Some Historical EBS News: 03/05/2018 – EMERGENT BIO 1Q ADJ LOSS/SHR 3.0C, EST. EPS 25.8C; 03/05/2018 – EMERGENT BIOSOLUTIONS INC EBS.N FY2018 SHR VIEW $2.38, REV VIEW $731.4 MLN — THOMSON REUTERS l/B/E/S; 25/04/2018 – EMERGENT BIOSOLUTIONS INC EBS.N : WELLS FARGO CUTS TO MARKET PERFORM FROM OUTPERFORM; 03/05/2018 – Emergent Biosolutions 1Q Loss/Shr 10c; 29/05/2018 – OTC Markets Group Welcomes Emergent Capital, Inc. to OTCQX; 12/04/2018 – Emergent BioSolutions Announces Successful Completion of Mutual Recognition Procedure for Market Authorisation of BioThrax in; 31/05/2018 – SPROTT INVESTS IN EMERGENT BEFORE GOLD BLOCKCHAIN PLATFORM; 26/03/2018 – Emergent Appoints Richard Lindahl as Chief Financial Officer; 26/03/2018 – Emergent BioSolutions Announces Executive Management Changes; 05/03/2018 GILEAD SCIENCES INC – NO PATIENTS IN BIKTARVY TREATMENT ARM DEMONSTRATED TREATMENT-EMERGENT RESISTANCE THROUGH 48 WEEKS

More notable recent Emergent BioSolutions Inc. (NYSE:EBS) news were published by: Benzinga.com which released: “Argus: Anthrax Vaccine Maker Emergent BioSolutions Poised For Earnings Growth” on June 13, 2018, also Benzinga.com with their article: “Benzinga’s Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid …” published on June 15, 2018, Seekingalpha.com published: “Premarket analyst action – healthcare” on June 12, 2018. More interesting news about Emergent BioSolutions Inc. (NYSE:EBS) were released by: Globenewswire.com and their article: “Emergent BioSolutions Announces $50 Million Expansion of Baltimore Fill/Finish Facility” published on June 07, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Top Upgrades, Downgrades For June 13, 2018” with publication date: June 13, 2018.

Analysts await Emergent BioSolutions Inc. (NYSE:EBS) to report earnings on August, 2. They expect $1.02 EPS, up 684.62% or $0.89 from last year’s $0.13 per share. EBS’s profit will be $50.83 million for 12.86 P/E if the $1.02 EPS becomes a reality. After $-0.03 actual EPS reported by Emergent BioSolutions Inc. for the previous quarter, Wall Street now forecasts -3,500.00% EPS growth.

Investors sentiment decreased to 1.77 in Q1 2018. Its down 0.25, from 2.02 in 2017Q4. It dropped, as 10 investors sold Emergent BioSolutions Inc. shares while 65 reduced holdings. 56 funds opened positions while 77 raised stakes. 38.34 million shares or 3.95% more from 36.89 million shares in 2017Q4 were reported. Millennium Ltd Com owns 917,065 shares or 0.06% of their US portfolio. Massachusetts Ma holds 27,656 shares. Usa Fincl Portformulas Corporation reported 5,885 shares or 0.07% of all its holdings. Mackay Shields Limited Liability Com holds 0.01% of its portfolio in Emergent BioSolutions Inc. (NYSE:EBS) for 17,580 shares. Phocas holds 0.72% or 153,106 shares. Matarin Ltd Liability Corporation invested in 0% or 351,830 shares. Gotham Asset Lc reported 0.02% of its portfolio in Emergent BioSolutions Inc. (NYSE:EBS). Kepos Cap Lp holds 0.03% or 10,134 shares. Public Employees Retirement Systems Of Ohio invested in 34,265 shares. Invesco Ltd reported 0.02% of its portfolio in Emergent BioSolutions Inc. (NYSE:EBS). Moreover, Arrowstreet Capital Partnership has 0.01% invested in Emergent BioSolutions Inc. (NYSE:EBS). 5,370 are owned by Proshare Advisors Lc. Strs Ohio has 0.02% invested in Emergent BioSolutions Inc. (NYSE:EBS). Citigroup owns 0% invested in Emergent BioSolutions Inc. (NYSE:EBS) for 38,896 shares. State Of Wisconsin Invest Board owns 34,000 shares or 0.01% of their US portfolio.

Among 7 analysts covering Emergent Biosolutions (NYSE:EBS), 4 have Buy rating, 0 Sell and 3 Hold. Therefore 57% are positive. Emergent Biosolutions has $6200 highest and $3300 lowest target. $51.75’s average target is -1.35% below currents $52.46 stock price. Emergent Biosolutions had 12 analyst reports since August 10, 2015 according to SRatingsIntel. Singular Research maintained the shares of EBS in report on Tuesday, June 28 with “Buy” rating. The stock has “Buy” rating by Singular Research on Tuesday, February 27. Wells Fargo initiated Emergent BioSolutions Inc. (NYSE:EBS) on Friday, February 19 with “Outperform” rating. The firm earned “Buy” rating on Monday, March 28 by Singular Research. Cowen & Co maintained the shares of EBS in report on Friday, July 14 with “Hold” rating. The stock has “Buy” rating by Chardan Capital Markets on Friday, April 15. On Monday, August 10 the stock rating was upgraded by Zacks to “Hold”. The rating was initiated by Cantor Fitzgerald on Monday, June 11 with “Buy”. The firm has “Hold” rating by Wells Fargo given on Tuesday, April 24.

Investors sentiment increased to 1.07 in 2018 Q1. Its up 0.02, from 1.05 in 2017Q4. It increased, as 14 investors sold Steven Madden, Ltd. shares while 77 reduced holdings. 39 funds opened positions while 58 raised stakes. 53.29 million shares or 0.23% more from 53.17 million shares in 2017Q4 were reported. Schroder Investment Mngmt Grp stated it has 0.06% of its portfolio in Steven Madden, Ltd. (NASDAQ:SHOO). Apg Asset Mgmt Nv reported 251,500 shares. 10,458 are held by Gam Ag. Eqis Mgmt has invested 0.02% of its portfolio in Steven Madden, Ltd. (NASDAQ:SHOO). The Massachusetts-based Rhumbline Advisers has invested 0.01% in Steven Madden, Ltd. (NASDAQ:SHOO). Legal General Group Inc Public Ltd accumulated 112,579 shares. Hotchkis & Wiley Cap Mgmt Ltd Liability Corporation holds 9,813 shares or 0% of its portfolio. Kornitzer Ks holds 165,985 shares or 0.12% of its portfolio. Ny State Common Retirement Fund has invested 0% in Steven Madden, Ltd. (NASDAQ:SHOO). Deutsche Bancshares Ag reported 458,138 shares. Fincl Bank Of Mellon Corporation holds 696,623 shares. 58,127 are owned by Los Angeles Capital & Equity Incorporated. The New Jersey-based Landscape Capital Mgmt Limited Liability Corporation has invested 0.84% in Steven Madden, Ltd. (NASDAQ:SHOO). Blackrock reported 7.04M shares. 455,803 were accumulated by Morgan Stanley.

Steven Madden, Ltd. designs, sources, markets, and sells fashion-forward name brand and private label footwear for women, men, and children worldwide. The company has market cap of $3.15 billion. The Company’s Wholesale Footwear segment provides footwear under Steve Madden Women's, Madden Girl, Steve Madden Men's, Madden, Dolce Vita, DV by Dolce Vita, Mad Love, Steven by Steve Madden, Report, Superga, Betsey Johnson, Betseyville, Steve Madden Kids, FREEBIRD by Steven, Stevies, B Brian Atwood, Blondo, and Madden NYC brands, as well as under the third party brands. It has a 26.43 P/E ratio. The companyÂ’s Wholesale Accessories segment offers Steve Madden, Steven by Steve Madden, Madden Girl, Betsey Johnson, Madden NYC, Big Buddha, B Brian Atwood, and Luv Betsey branded; and private label fashion handbags and accessories to department stores, mass merchants, value priced retailers, online retailers, and specialty stores; and markets and sells cold weather accessories, fashion scarves, wraps, and other trend accessories under the Cejon, Steve Madden, Betsey Johnson, and Big Buddha brand names, as well as private labels to department stores and specialty stores.

Since December 18, 2017, it had 0 insider purchases, and 6 selling transactions for $7.40 million activity. 6,000 shares were sold by Frieders Karla, worth $319,740 on Wednesday, May 30. The insider MIGLIORINI PETER sold $54,178. The insider VARELA AMELIA sold $5.07 million. $292,663 worth of Steven Madden, Ltd. (NASDAQ:SHOO) was sold by SINHA AWADHESH K. Rosenfeld Edward R. sold $1.51 million worth of stock or 33,000 shares. DHARIA ARVIND sold $255,000 worth of stock or 5,000 shares.

Steven Madden, Ltd. (NASDAQ:SHOO) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *